Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

The HK2 Dependent "Warburg Effect" and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate.

Lis P, Dyląg M, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Molecules. 2016 Dec 15;21(12). pii: E1730. Review.

2.

Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma.

Niedźwiecka K, Dyląg M, Augustyniak D, Majkowska-Skrobek G, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Oct 4;7(40):65614-65626. doi: 10.18632/oncotarget.11592.

3.

The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Azevedo-Silva J, Queirós O, Baltazar F, Ułaszewski S, Goffeau A, Ko YH, Pedersen PL, Preto A, Casal M.

J Bioenerg Biomembr. 2016 Aug;48(4):349-62. doi: 10.1007/s10863-016-9670-z. Epub 2016 Jul 25. Review.

PMID:
27457582
4.

Screening the yeast genome for energetic metabolism pathways involved in a phenotypic response to the anti-cancer agent 3-bromopyruvate.

Lis P, Jurkiewicz P, Cal-Bąkowska M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Oncotarget. 2016 Mar 1;7(9):10153-73. doi: 10.18632/oncotarget.7174.

5.

Transport of 3-bromopyruvate across the human erythrocyte membrane.

Sadowska-Bartosz I, Soszyński M, Ułaszewski S, Ko Y, Bartosz G.

Cell Mol Biol Lett. 2014 Jun;19(2):201-14. doi: 10.2478/s11658-014-0189-1. Epub 2014 Apr 9.

PMID:
24715475
6.

Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy.

Majkowska-Skrobek G, Augustyniak D, Lis P, Bartkowiak A, Gonchar M, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Anticancer Drugs. 2014 Jul;25(6):673-82. doi: 10.1097/CAD.0000000000000094.

PMID:
24557015
7.

3-Bromopyruvate: a novel antifungal agent against the human pathogen Cryptococcus neoformans.

Dyląg M, Lis P, Niedźwiecka K, Ko YH, Pedersen PL, Goffeau A, Ułaszewski S.

Biochem Biophys Res Commun. 2013 May 3;434(2):322-7. doi: 10.1016/j.bbrc.2013.02.125. Epub 2013 Mar 26.

PMID:
23541578
8.

Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae.

Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A, Ułaszewski S.

J Bioenerg Biomembr. 2012 Feb;44(1):155-61. doi: 10.1007/s10863-012-9421-8. Epub 2012 Feb 23.

PMID:
22359102
9.

Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate.

Queirós O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M, Ko YH, Pedersen PL, Baltazar F, Casal M.

J Bioenerg Biomembr. 2012 Feb;44(1):141-53. doi: 10.1007/s10863-012-9418-3. Epub 2012 Feb 17.

PMID:
22350013
10.

A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside.

Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL.

J Bioenerg Biomembr. 2012 Feb;44(1):163-70. doi: 10.1007/s10863-012-9417-4. Epub 2012 Feb 11.

PMID:
22328020
11.

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Mathupala SP, Ko YH, Pedersen PL.

Semin Cancer Biol. 2009 Feb;19(1):17-24. doi: 10.1016/j.semcancer.2008.11.006. Epub 2008 Dec 3. Review.

12.
13.

Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL.

Biochem Biophys Res Commun. 2004 Nov 5;324(1):269-75.

PMID:
15465013
14.

Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma.

Geschwind JF, Georgiades CS, Ko YH, Pedersen PL.

Expert Rev Anticancer Ther. 2004 Jun;4(3):449-57. Review.

PMID:
15161443
15.

Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.

Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL.

Cancer Res. 2002 Jul 15;62(14):3909-13.

16.

Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.

Ko YH, Pedersen PL, Geschwind JF.

Cancer Lett. 2001 Nov 8;173(1):83-91.

PMID:
11578813
17.

Use of chemical modification in the crystallization of isocitrate lyase from Escherichia coli.

Abeysinghe SI, Baker PJ, Rice DW, Rodgers HF, Stillman TJ, Ko YH, McFadden BA, Nimmo HG.

J Mol Biol. 1991 Jul 5;220(1):13-6.

PMID:
2067012
18.

Alkylation of isocitrate lyase from Escherichia coli by 3-bromopyruvate.

Ko YH, McFadden BA.

Arch Biochem Biophys. 1990 May 1;278(2):373-80.

PMID:
2183722

Supplemental Content

Loading ...
Support Center